Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T7US
|
|||
| Former ID |
DAP000908
|
|||
| Drug Name |
Eprosartan
|
|||
| Synonyms |
133040-01-4; Teveten; F-108566; F 108566; UNII-2KH13Z0S0Y; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEMBL813; SK-108566; 2KH13Z0S0Y; CHEBI:4814; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK&F 108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; [3H]eprosartan
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24N2O4S
|
|||
| Canonical SMILES |
CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O
|
|||
| InChI |
1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
|
|||
| InChIKey |
OROAFUQRIXKEMV-LDADJPATSA-N
|
|||
| CAS Number |
CAS 133040-01-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9670, 7979177, 8616481, 14929623, 17398013, 26757976, 39289969, 46506765, 48415948, 49658621, 49830795, 50064350, 50303490, 81092802, 85209073, 91612944, 92308966, 93166188, 103213560, 103924435, 113854438, 117814116, 121277912, 126682167, 127329712, 127329713, 127329714, 127329715, 127329716, 127329717, 127329718, 127329719, 127329720, 127329721, 127329722, 127329723, 131835100, 134223577, 134338185, 135026481, 135650236, 136367951, 137002491, 142300349, 144115951, 162161427, 163389404, 164814942, 175266444, 176484078
|
|||
| ChEBI ID |
CHEBI:4814
|
|||
| ADReCS Drug ID | BADD_D00790 | |||
| SuperDrug ATC ID |
C09CA02
|
|||
| SuperDrug CAS ID |
cas=133040014
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin II receptor type-1 (AGTR1) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Renin-angiotensin system | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Muscle/Heart Contraction | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Angiopoietin receptor Tie2-mediated signaling | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 588). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. | |||
| REF 4 | Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor. J Recept Res. 1993;13(5):849-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.